Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 May;69(5):868–874. doi: 10.1038/bjc.1994.168

Multidrug resistance circumvention by a new triazinoaminopiperidine derivative S9788 in vitro: definition of the optimal schedule and comparison with verapamil.

A M Julia 1, H Roché 1, M Berlion 1, C Lucas 1, G Milano 1, J Robert 1, J P Bizzari 1, P Canal 1
PMCID: PMC1968895  PMID: 8180016

Abstract

The current work was undertaken to investigate the importance of exposure sequence and duration in achieving the maximum reversal action of S9788 on doxorubicin (DOX) cytotoxicity against cells that exhibit the (MDR) multidrug resistance phenotype: the MCF7/DOX cell line. Accumulation and release of DOX were examined in this cell line. The reversal effect was compared with that obtained with verapamil. S9788 activity was schedule dependent: when comparing incubation with S9788 before or after treatment with DOX, the best reversal factor was obtained in the case of a post-treatment incubation (65.6 +/- 7.7 vs 20.8 +/- 7.0). S9788 was a more potent modulating agent than verapamil, whatever the schedule of exposure of the cells to the reversal agent. The reversal of resistance after short-term DOX exposures was caused not only by prolonged cellular accumulation of DOX, but also by its prolonged retention after transfer of cells to DOX-free medium. A relationship was noted between cellular exposure to DOX and the cytotoxic effect, and so the reversal of resistance induced by S9788 appears to be directly linked to the level of cell exposure to DOX. This work provided a rationale for improving the schedule of administration of S9788 in clinical trials.

Full text

PDF
868

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akiyama S., Shiraishi N., Kuratomi Y., Nakagawa M., Kuwano M. Circumvention of multiple-drug resistance in human cancer cells by thioridazine, trifluoperazine, and chlorpromazine. J Natl Cancer Inst. 1986 May;76(5):839–844. [PubMed] [Google Scholar]
  2. Barrand M. A., Rhodes T., Center M. S., Twentyman P. R. Chemosensitisation and drug accumulation effects of cyclosporin A, PSC-833 and verapamil in human MDR large cell lung cancer cells expressing a 190k membrane protein distinct from P-glycoprotein. Eur J Cancer. 1993;29A(3):408–415. doi: 10.1016/0959-8049(93)90397-x. [DOI] [PubMed] [Google Scholar]
  3. Batist G., Tulpule A., Sinha B. K., Katki A. G., Myers C. E., Cowan K. H. Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J Biol Chem. 1986 Nov 25;261(33):15544–15549. [PubMed] [Google Scholar]
  4. Bruno N. A., Slate D. L. Effect of exposure to calcium entry blockers on doxorubicin accumulation and cytotoxicity in multidrug-resistant cells. J Natl Cancer Inst. 1990 Mar 7;82(5):419–424. doi: 10.1093/jnci/82.5.419. [DOI] [PubMed] [Google Scholar]
  5. Cairo M. S., Siegel S., Anas N., Sender L. Clinical trial of continuous infusion verapamil, bolus vinblastine, and continuous infusion VP-16 in drug-resistant pediatric tumors. Cancer Res. 1989 Feb 15;49(4):1063–1066. [PubMed] [Google Scholar]
  6. Carl J. Drug-resistance patterns assessed from tumor marker analysis. J Natl Cancer Inst. 1989 Nov 1;81(21):1631–1639. doi: 10.1093/jnci/81.21.1631. [DOI] [PubMed] [Google Scholar]
  7. Cass C. E., Janowska-Wieczorek A., Lynch M. A., Sheinin H., Hindenburg A. A., Beck W. T. Effect of duration of exposure to verapamil on vincristine activity against multidrug-resistant human leukemic cell lines. Cancer Res. 1989 Nov 1;49(21):5798–5804. [PubMed] [Google Scholar]
  8. Coldman A. J., Goldie J. H. Role of mathematical modeling in protocol formulation in cancer chemotherapy. Cancer Treat Rep. 1985 Oct;69(10):1041–1048. [PubMed] [Google Scholar]
  9. Coley H. M., Amos W. B., Twentyman P. R., Workman P. Examination by laser scanning confocal fluorescence imaging microscopy of the subcellular localisation of anthracyclines in parent and multidrug resistant cell lines. Br J Cancer. 1993 Jun;67(6):1316–1323. doi: 10.1038/bjc.1993.244. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Cros S., Guilbaud N., Berlion M., Dunn T., Regnier G., Dhainaut A., Atassi G., Bizzari J. P. In vivo evidence of complete circumvention of vincristine resistance by a new triazinoaminopiperidine derivative S 9788 in P388/VCR leukemia model. Cancer Chemother Pharmacol. 1992;30(6):491–494. doi: 10.1007/BF00685604. [DOI] [PubMed] [Google Scholar]
  11. DeGregorio M. W., Ford J. M., Benz C. C., Wiebe V. J. Toremifene: pharmacologic and pharmacokinetic basis of reversing multidrug resistance. J Clin Oncol. 1989 Sep;7(9):1359–1364. doi: 10.1200/JCO.1989.7.9.1359. [DOI] [PubMed] [Google Scholar]
  12. Dhainaut A., Régnier G., Atassi G., Pierré A., Léonce S., Kraus-Berthier L., Prost J. F. New triazine derivatives as potent modulators of multidrug resistance. J Med Chem. 1992 Jun 26;35(13):2481–2496. doi: 10.1021/jm00091a017. [DOI] [PubMed] [Google Scholar]
  13. Ganapathi R., Grabowski D. Enhancement of sensitivity to adriamycin in resistant P388 leukemia by the calmodulin inhibitor trifluoperazine. Cancer Res. 1983 Aug;43(8):3696–3699. [PubMed] [Google Scholar]
  14. Ganapathi R., Grabowski D., Rouse W., Riegler F. Differential effect of the calmodulin inhibitor trifluoperazine on cellular accumulation, retention, and cytotoxicity of anthracyclines in doxorubicin (adriamycin)-resistant P388 mouse leukemia cells. Cancer Res. 1984 Nov;44(11):5056–5061. [PubMed] [Google Scholar]
  15. Gervasoni J. E., Jr, Fields S. Z., Krishna S., Baker M. A., Rosado M., Thuraisamy K., Hindenburg A. A., Taub R. N. Subcellular distribution of daunorubicin in P-glycoprotein-positive and -negative drug-resistant cell lines using laser-assisted confocal microscopy. Cancer Res. 1991 Sep 15;51(18):4955–4963. [PubMed] [Google Scholar]
  16. Gottesman M. M., Pastan I. Resistance to multiple chemotherapeutic agents in human cancer cells. Trends Pharmacol Sci. 1988 Feb;9(2):54–58. doi: 10.1016/0165-6147(88)90117-4. [DOI] [PubMed] [Google Scholar]
  17. Huet S., Chapey C., Robert J. Reversal of multidrug resistance by a new lipophilic cationic molecule, S9788. Comparison with 11 other MDR-modulating agents in a model of doxorubicin-resistant rat glioblastoma cells. Eur J Cancer. 1993;29A(10):1377–1383. doi: 10.1016/0959-8049(93)90005-z. [DOI] [PubMed] [Google Scholar]
  18. Keizer H. G., Schuurhuis G. J., Broxterman H. J., Lankelma J., Schoonen W. G., van Rijn J., Pinedo H. M., Joenje H. Correlation of multidrug resistance with decreased drug accumulation, altered subcellular drug distribution, and increased P-glycoprotein expression in cultured SW-1573 human lung tumor cells. Cancer Res. 1989 Jun 1;49(11):2988–2993. [PubMed] [Google Scholar]
  19. Luk C. K., Tannock I. F. Flow cytometric analysis of doxorubicin accumulation in cells from human and rodent cell lines. J Natl Cancer Inst. 1989 Jan 4;81(1):55–59. doi: 10.1093/jnci/81.1.55. [DOI] [PubMed] [Google Scholar]
  20. Léonce S., Pierré A., Anstett M., Pérez V., Genton A., Bizzari J. P., Atassi G. Effects of a new triazinoaminopiperidine derivative on adriamycin accumulation and retention in cells displaying P-glycoprotein-mediated multidrug resistance. Biochem Pharmacol. 1992 Nov 3;44(9):1707–1715. doi: 10.1016/0006-2952(92)90063-o. [DOI] [PubMed] [Google Scholar]
  21. Muller C., Chatelut E., Gualano V., De Forni M., Huguet F., Attal M., Canal P., Laurent G. Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion. Cancer Chemother Pharmacol. 1993;32(5):379–384. doi: 10.1007/BF00735923. [DOI] [PubMed] [Google Scholar]
  22. Ozols R. F., Cunnion R. E., Klecker R. W., Jr, Hamilton T. C., Ostchega Y., Parrillo J. E., Young R. C. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol. 1987 Apr;5(4):641–647. doi: 10.1200/JCO.1987.5.4.641. [DOI] [PubMed] [Google Scholar]
  23. Pennock G. D., Dalton W. S., Roeske W. R., Appleton C. P., Mosley K., Plezia P., Miller T. P., Salmon S. E. Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration. J Natl Cancer Inst. 1991 Jan 16;83(2):105–110. doi: 10.1093/jnci/83.2.105. [DOI] [PubMed] [Google Scholar]
  24. Pierré A., Dunn T. A., Kraus-Berthier L., Léonce S., Saint-Dizier D., Régnier G., Dhainaut A., Berlion M., Bizzari J. P., Atassi G. In vitro and in vivo circumvention of multidrug resistance by Servier 9788, a novel triazinoaminopiperidine derivative. Invest New Drugs. 1992 Aug;10(3):137–148. doi: 10.1007/BF00877238. [DOI] [PubMed] [Google Scholar]
  25. Pérez V., Pierré A., Léonce S., Anstett M., Prost J. F., Atassi G. Caractérisation in vitro de l'activité du S9788, un nouveau modulateur de la résistance multidrogue. Bull Cancer. 1993 Apr;80(4):310–325. [PubMed] [Google Scholar]
  26. Ramu A., Spanier R., Rahamimoff H., Fuks Z. Restoration of doxorubicin responsiveness in doxorubicin-resistant P388 murine leukaemia cells. Br J Cancer. 1984 Oct;50(4):501–507. doi: 10.1038/bjc.1984.207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Schuurhuis G. J., Broxterman H. J., Cervantes A., van Heijningen T. H., de Lange J. H., Baak J. P., Pinedo H. M., Lankelma J. Quantitative determination of factors contributing to doxorubicin resistance in multidrug-resistant cells. J Natl Cancer Inst. 1989 Dec 20;81(24):1887–1892. doi: 10.1093/jnci/81.24.1887. [DOI] [PubMed] [Google Scholar]
  28. Sehested M., Skovsgaard T., van Deurs B., Winther-Nielsen H. Increased plasma membrane traffic in daunorubicin resistant P388 leukaemic cells. Effect of daunorubicin and verapamil. Br J Cancer. 1987 Dec;56(6):747–751. doi: 10.1038/bjc.1987.282. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Solary E., Caillot D., Chauffert B., Casasnovas R. O., Dumas M., Maynadie M., Guy H. Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia. J Clin Oncol. 1992 Nov;10(11):1730–1736. doi: 10.1200/JCO.1992.10.11.1730. [DOI] [PubMed] [Google Scholar]
  30. Toffoli G., Tumiotto L., Gigante M., Dall'Arche M. G., Perin T., Boiocchi M. Increased chemosensitivity to doxorubicin of intrinsically multidrug-resistant human colon carcinoma cells by prolonged exposure to verapamil. Eur J Cancer. 1993;29A(12):1776–1778. doi: 10.1016/0959-8049(93)90123-w. [DOI] [PubMed] [Google Scholar]
  31. Tsuruo T., Iida H., Kitatani Y., Yokota K., Tsukagoshi S., Sakurai Y. Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drug-resistant tumor cells. Cancer Res. 1984 Oct;44(10):4303–4307. [PubMed] [Google Scholar]
  32. Tsuruo T., Iida H., Nojiri M., Tsukagoshi S., Sakurai Y. Circumvention of vincristine and Adriamycin resistance in vitro and in vivo by calcium influx blockers. Cancer Res. 1983 Jun;43(6):2905–2910. [PubMed] [Google Scholar]
  33. Tsuruo T., Iida H., Tsukagoshi S., Sakurai Y. Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res. 1982 Nov;42(11):4730–4733. [PubMed] [Google Scholar]
  34. Tsuruo T., Iida H., Tsukagoshi S., Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 1981 May;41(5):1967–1972. [PubMed] [Google Scholar]
  35. Twentyman P. R. Modification of cytotoxic drug resistance by non-immuno-suppressive cyclosporins. Br J Cancer. 1988 Mar;57(3):254–258. doi: 10.1038/bjc.1988.55. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Yahanda A. M., Alder K. M., Fisher G. A., Brophy N. A., Halsey J., Hardy R. I., Gosland M. P., Lum B. L., Sikic B. I. Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. J Clin Oncol. 1992 Oct;10(10):1624–1634. doi: 10.1200/JCO.1992.10.10.1624. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES